Pipeline Therapeutics is a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for neuroregeneration, including synaptogenesis, remyelination and axonal repair. The company's lead clinical program, PIPE-505, is currently enrolling patients in a phase 1/2a study to treat sensorineural hearing loss (SNHL) associated with speech-in-noise disability. The company has also initiated a Phase 1 healthy volunteer study for its second clinical program, PIPE-307, targeting multiple sclerosis. In addition, Pipeline has a portfolio of further programs addressing a range of neurological disorders and conditions.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 02/11/21 | $80,000,000 | Series C |
Casdin Capital Cleva Pharma Franklin Templeton Perceptive Advisors Red Tree Venture Captial Samsara BioCapital Sectoral Asset Management Suvretta Capital Management Versant Ventures | undisclosed |
